Research
Commonly used drug kills leukemia cells early by acting mainly on RNA, not DNA
The Brief
- A commonly used drug, azacitidine, has been a major treatment for high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) for more than two decades.
- The drug was long thought to work through DNA by stripping off chemical tags that keep genes silenced.
- A new report says azacitidine kills leukemia cells early mainly by acting on RNA rather than DNA.
Why it matters
Identifying RNA rather than DNA as the main target of a widely used leukemia drug changes how its mechanism is understood, which could inform future treatment design.
Who’s affected
- researchers in leukemia and blood cancers
- clinicians and patients who use azacitidine for MDS and AML
- #azacitidine
- #leukemia
- #rna
- #dna
- #cancer-research
For more than two decades, azacitidine has been a major treatment for blood cancers such as high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The drug was thought to work through DNA, by stripping off the chemical tags that keep genes silenced and…